Company Overview and News

 
DFCC Bank partners with Sathosa Motors to offer attractive leasing solutions

2016-10-19 bizenglish.adaderana.lk
DFCC Bank signed a Memorandum of Understanding (MoU) with Sathosa Motors on 7th October 2016 at the DFCC Head office. The CEOs of the two institutions signed the MoU, which will facilitate the leasing of Isuzu branded vehicles for DFCC Bank’s customers. Sathosa Motors is the sole authorised agent in Sri Lanka for Isuzu Commercial vehicles, which is the No.1 Japanese brand for commercial vehicles in the world.

 
ICRA Lanka reaffirms Access Engineering [SL] A+ long-term ratings

2016-09-27 lankabusinessonline
ICRA Lanka Limited, subsidiary of ICRA Ltd, a group company of Moody’s Investors Service, has reaffirmed the Issuer rating of [SL]A+ (pronounced S L A plus1) with stable outlook for Access Engineering PLC (“AEL”/ “the Company”). ICRA Lanka has also reaffirmed the Issue Rating of [SL]A+ for the company’s LKR 5,000 Mn Senior Unsecured Redeemable Debenture programme.

 
Isuzu owners to receive valuable extended warranty option from SML

2016-09-18 bizenglish.adaderana.lk
Sathosa Motors PLC (SML) announced the launch of a valuable new extended warranty offer for Isuzu vehicle owners in Sri Lanka.

 
Sri Lanka’s Access Engineering net down 13-pct in June quarter

2016-07-28 lankabusinessonline
July 28, 2016 (LBO) – Profits at Sri Lanka’s Access Engineering group fell 13 percent to 524 million rupees in the June 2016 quarter from a year earlier amid higher expenses, interim accounts showed.

 
Access Engineering net up 5.1 pct, IPO for SML Frontier planned

2016-07-22 lankabusinessonline
July 22, 2016 (LBO) – Sri Lanka’s Access Engineering said group net profits grew 5.1 percent to 2.46 billion rupees in the year to March 2016, with the civil engineering firm facing a slow down in the global and local economy.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...